The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine (Oral-AZA) in combination with venetoclax (VEN) for treatment of acute myeloid leukemia.
 
Shaun Fleming
Honoraria - Amgen; Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Novartis; Pfizer
Speakers' Bureau - Amgen; Pfizer
Research Funding - Amgen
 
Gail J. Roboz
Consulting or Advisory Role - Abbvie; Amgen; Argenx; AstraZeneca; Bluebird Bio; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Ellipses Pharma; GlaxoSmithKline; Janssen; Jasper Therapeutics; Jazz Pharmaceuticals; Molecular Partners; Novartis; Pfizer; Roche; Syndax; Takeda
Research Funding - Janssen
 
Amir Tahmasb Fathi
Consulting or Advisory Role - Abbvie; Agios; Amgen; Astellas Pharma; Autolus; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; EnClear Therapies; FORMA Therapeutics; Genentech; Immunogen; Ipsen; Kite, a Gilead company; Mablytics; MorphoSys; Novartis; Orum Therapeutics; Pfizer; PureTech; Rigel; SERVIER; Takeda
Research Funding - Abbvie (Inst); agios (Inst); Bristol-Myers Squibb (Inst); SERVIER (Inst)
 
Tian Yi Zhang
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
Andrew Wei
Honoraria - Abbvie; Agios; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; Gilead Sciences; Janssen; Jazz Pharmaceuticals; Novartis; Pfizer; Roche; SERVIER
Consulting or Advisory Role - Abbvie; Aculeus Therapeutics; Agios; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; Gilead Sciences; Janssen; Jazz Pharmaceuticals; Novartis; Pfizer; Roche; SERVIER; Shoreline Biosciences
Speakers' Bureau - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Novartis; SERVIER
Research Funding - Abbvie; Amgen; Astex Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; Janssen; Novartis; SERVIER; Syndax
Patents, Royalties, Other Intellectual Property - Walter and Eliza Hall Institute of Medical Research
 
Hetty E Carraway
Consulting or Advisory Role - BMS; Jazz Pharmaceuticals; Novartis
Speakers' Bureau - Agios; BMSi; Jazz Pharmaceuticals; Novartis; Stemline Therapeutics
Research Funding - Celgene
Travel, Accommodations, Expenses - Jazz Pharmaceuticals; Novartis
Other Relationship - Abbvie; Astex Pharmaceuticals; Syndax; Takeda
 
Leanne Holes
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Abbvie; Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Abbvie
 
Erica Petrlik
Employment - Bristol-Myers Squibb/Celgene
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
 
Thomas Prebet
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Daniel Lopes de Menezes
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
 
Iryna Bluemmert
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Hao Sun
Employment - Bristol-Myers Squibb
 
Farhad Ravandi
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Jazz Pharmaceuticals; Novartis; Pfizer; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Certara Inc; Jazz Pharmaceuticals; Syros Pharmaceuticals; Taiho Oncology
Research Funding - Amgen; Astex Pharmaceuticals; Biomea Fusion; Bristol-Myers Squibb; Cellerant; Macrogenics; Prelude Therapeutics; Selvita; Syros Pharmaceuticals; Taiho Oncology; Xencor